메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Neopharma Technologies Appoints Exchange Listing to Manage U.S. IPO

NEW YORK, Aug. 5, 2025 -- Neopharma Technologies Ltd (NTL), a leading MedTech company specializing in digital drug and impairment testing for workplace and public safety, has appointed Exchange Listing, LLC to manage its upcoming U.S. initial public offering (IPO), with plans to list on the NASDAQ Stock Exchange. Neopharma has developed NEOVAULT®, the world's first integrated chain-of-custody and data management platform for point-of-care (POC) drug testing. Paired with its NEOTEST® range of regulatory-grade oral and urine screening devices, NEOVAULT® provides a sec
- 김갑성 기자
- 2025-08-05 21:00
BON Announces Reciept of Nasdaq Compliance Letter

XI'AN, China, Aug. 5, 2025 -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced reciept of compliance notification from the Nasdaq Stock Market LLC. As previously reported on a Form 6-K filed with the U.S. Securities and Exchange Commission on July 11, 2025, Bon Natural Life Limited ( "the Company") received notification from the Nasdaq Hearings Panel (the "Panel") that the Company had regained compliance with Listing
- 김갑성 기자
- 2025-08-05 21:00
iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application

[ 메디채널 김갑성 기자 ] • Successful validation of payloaded anti-colibactin toxin phage using IMPA™ technology • Demonstrated 'Dual-target Therapeutic Strategy' by bacterial eradication and toxin neutralization • Filed the US patent application for the candidate substance and preclinical studies including PoC underway BOSTON and SEOUL, South Korea, Aug. 5, 2025 -- Recently, a specific genotype of E. coli that may cause colorectal cancer has been detected in commonly eaten leafy vegetables such as lettuce, raising consumer concerns. Among these strains, pks+ E. coli is of particular conce
- 김갑성 기자
- 2025-08-05 20:00
Court Sides with Cardiovalve in Edwards patent spat

HANGZHOU, China, Aug. 5, 2025 -- Venus Medtech (Hangzhou) Inc. ("Venus Medtech", Stock Code: 02500.HK) recently announced a decisive legal victory for its wholly-owned subsidiary Cardiovalve Ltd. ("Cardiovalve") against Edwards Lifesciences Corporation and Edwards Lifesciences LLC. (collectively "Edwards"). The United States Court of Appeals for the Federal Circuit ("CAFC") has formally issued its mandate in Case 23-1515, affirming the Patent Trial and Appeal Board's ("PTAB") December 2022 ruling that upheld the validity of Cardiovalve's paten
- 김갑성 기자
- 2025-08-05 20:00
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight

- 13-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of two oral formulations of ASC30, a once-daily tablet, in 125 participants with obesity or overweight. - All 125 participants enrolled in just over one month; topline data expected in the fourth quarter of 2025. HONG KONG, Aug. 5, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today completion of enrollment in its U.S. 13-week Phase IIa study evaluating ASC30, a small molecule oral GLP-1 receptor (GLP-1R) agonist for the treatment of obesity (NCT0700290
- 김갑성 기자
- 2025-08-05 18:50
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer. It will also support the potential development of a bespoke AI-powered predictive model aimed at optimizing outcomes for indivi
- 김갑성 기자
- 2025-08-05 18:40
Fapon Biopharma Announces the enrollment of the First Patient in the Phase I Clinical Trial of FP008, A First-in-Class Immunotherapy for Solid Tumors

DONGGUAN, China, Aug 5, 2025 -- Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient enrollment in China for its Phase I clinical trial of FP008 , a first-in-class immunotherapy for solid tumors, at Zhejiang Cancer Hospital. The patient has completed the Dose Limiting Toxicity (DLT) observation period with a favorable safety profile. The trial aims to evaluate the safety and tolerability of FP008 in patients with advanced solid tumors. As the latest next generation of immuno-oncology (IO) app
- 김갑성 기자
- 2025-08-05 16:30
Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion

GUANGZHOU, China, Aug. 5, 2025 -- Sunshine Lake Pharma Co., Ltd. (06887.HK) announced that the company will officially list on the Hong Kong Stock Exchange on August 7th. Through this integration, the company has effectively combined its expertise in drug R&D with the mature nationwide sales network resources of Sunshine Lake Pharma Co., Ltd. This forms an R&D-manufacturing-sales closed loop to accelerate global operations, thereby driving value reshaping and laying a more solid foundation for future sustainable development, including international expansion. This year, propell
- 김갑성 기자
- 2025-08-05 15:34
Chugai Pharma Taiwan Honored at the AREA 2025 for its Social Empowerment and Green Innovation

BANGKOK, Aug. 4, 2025 -- Chugai Pharma Taiwan (CPT), a subsidiary of Chugai Pharmaceutical Co., Ltd. in Japan, has been recognized in both the Social Empowerment and Green Leadership categories at the Asia Responsible Enterprise Awards (AREA) 2025. These recognitions highlight the company's exceptional efforts in driving community impact and environmental sustainability through healthcare-focused innovation and compassion. In the Social Empowerment category, CPT was recognized for its heartfelt and impactful charitable initiatives. Through its annual charity cycling event, CPT not only
- 김갑성 기자
- 2025-08-05 13:02
TSH Biopharm Honored for Social Empowerment and Green Leadership at the Asia Responsible Enterprise Awards 2025

BANGKOK, Aug. 4, 2025 -- TSH Biopharm Corporation Ltd. has been recognized with dual honors at the Asia Responsible Enterprise Awards 2025, receiving accolades for the Green Leadership and Social Empowerment categories. The awards reflect the company's growing influence as a purpose-driven pharmaceutical firm that integrates sustainability and human well-being into its corporate DNA. TSH Biopharm's Green Leadership accolade celebrates its signature initiative, "Sowing with Heart," which redefines the connection between health and the environment. In a pioneering effort, the c
- 김갑성 기자
- 2025-08-05 12:27

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-09-05_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 05일 15시 40분